Scalper1 News
Valeant Pharmaceuticals (VRX) is reportedly mulling a higher bid for Salix Pharmaceuticals (SLXP) even as Valeant investor Bill Ackman said it won’t “overpay.” Valeant is considering raising its all-cash offer to above $160 a share, sources told the New York Times, though a specific figure wasn’t cited. Valeant last month agreed to pay $158 a share for Salix in an all-cash deal worth $10 billion, or $14.5 billion including assumed debt. But on Scalper1 News
Scalper1 News